


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A ~~pharmaceutical composition for use in the treatment or prevention of diseases~~ method for treating or preventing a disease, wherein where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3 (Flt3), ~~and/or its~~ somatic cell variant (Flt3-ITD), or a combination thereof is therapeutically or prophylactically effective, ~~which comprises~~ comprising administering a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier, to a mammal:



wherein

X represents CH or N,

Z represents O or S,

R¹, R², and R³, which may be the same or different, represent

a hydrogen atom,

hydroxyl,

halogen,

nitro,

cyano,

amino,

C₁₋₆ alkyl,

C₂₋₆ alkenyl,

C₂₋₆ alkynyl,

C₁₋₆ alkoxy,

-(C=O)OR^C wherein R^C represents a hydrogen atom or C₁₋₄ alkyl, or

-(C=O)NR^dR^e wherein R^d and R^e, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl,

the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups, which may be represented by R¹, R², and R³, are optionally substituted by hydroxyl; a halogen atom; C₁₋₆ alkoxy; C₁₋₆ alkylcarbonyl; carboxyl; C₁₋₆ alkoxy carbonyl; -(C=O)-NR¹⁰R¹¹ wherein R¹⁰ and R¹¹, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl optionally substituted by hydroxyl, or R¹⁰ and R¹¹ may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C₁₋₆ alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C₁₋₆ alkyl group is further optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, a halogen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are further optionally substituted by hydroxyl,

C₁₋₆ alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic group;

one or two hydrogen atoms on the amino group, which may be represented by R¹, R², and R³, are optionally substituted by C₁₋₆ alkyl which is further optionally substituted by hydroxyl or C₁₋₆ alkoxy;

R⁴ represents a hydrogen atom;

all of R⁵, R⁶, R⁷, and R⁸ represent a hydrogen atom, or any one or two of R⁵, R⁶, R⁷, and R⁸ represent a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, amino, or hydroxyl with all the remaining groups representing a hydrogen atom, and

R⁹ represents C₁₋₄ alkyl substituted by a substituent selected from the group consisting of a saturated three- to nine-membered carbocyclic group optionally substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, or hydroxyl; i-propyl optionally substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, or hydroxyl; t-butyl optionally substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, or hydroxyl; C₁₋₄ alkoxy; and -NR^aR^b wherein R^a and R^b, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl optionally substituted by hydroxyl, or R^a and R^b may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R⁹ represents a saturated three- to nine-membered carbocyclic group optionally substituted by one to three C₁₋₄ alkyl groups.

Claim 2 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein the disease where the inhibition of autophosphorylation of Flt3, ~~and/or~~ Flt3-ITD, or a combination thereof is therapeutically or prophylactically effective is hematopoietic malignancy.

Claim 3 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 2, wherein the hematopoietic malignancy is acute myelocytic leukemia or myelodysplastic syndrome.

Claim 4 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein the disease where the inhibition of autophosphorylation of Flt3, ~~and/or~~ Flt3-ITD, or a combination thereof is therapeutically or prophylactically effective is an immunological disease caused by abnormal proliferation of B cells, dendritic cells, or natural killer cells.

Claim 5 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, which is used in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 is therapeutically or prophylactically effective.

Claim 6 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 5, wherein the disease where the inhibition of autophosphorylation of Flt3 is therapeutically or prophylactically effective is hematopoietic malignancy.

Claim 7 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 6, wherein the hematopoietic malignancy is acute myelocytic leukemia or myelodysplastic syndrome.

Claim 8 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 5, wherein the disease where the inhibition of autophosphorylation of Flt3 is therapeutically or prophylactically effective is an immunological disease caused by abnormal proliferation of B cells, dendritic cells, or natural killer cells.

Claim 9 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, which is used in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3-ITD is therapeutically or prophylactically effective.

Claim 10 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 9, wherein the disease where the inhibition of autophosphorylation of Flt3-ITD is therapeutically or prophylactically effective is hematopoietic malignancy.

Claim 11 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 10, wherein the hematopoietic malignancy is acute myelocytic leukemia or myelodysplastic syndrome.

Claim 12 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 9, wherein the disease where the inhibition of autophosphorylation of Flt3-ITD is

therapeutically or prophylactically effective is an immunological disease caused by abnormal proliferation of B cells, dendritic cells, or natural killer cells.

Claim 13 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 12~~ claim 1, wherein X represents CH and Z represents O.

Claim 14 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 13~~ claim 1, wherein R¹ represents a hydrogen atom and R² and R³, which may be the same or different, represent optionally substituted C₁₋₆ alkoxy.

Claim 15 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 14~~ claim 1, wherein R¹ represents a hydrogen atom, R² and R³, which may be the same or different, represent -O-(CH₂)_p-R¹² wherein p is an integer of 0 to 6, -(CH₂)_p- is optionally substituted by C₁₋₆ alkyl, hydroxyl, or a halogen atom, and R¹² represents a hydrogen atom; hydroxyl; a halogen atom; C₁₋₆ alkoxy; C₁₋₆ alkylcarbonyl; carboxyl; C₁₋₆ alkoxycarbonyl; -(C=O)-NR¹³R¹⁴ wherein R¹³ and R¹⁴, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl optionally substituted by hydroxyl, or R¹³ and R¹⁴ may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C₁₋₆ alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C₁₋₆ alkyl group

is further optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are further optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring.

Claim 16 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 15~~ claim 1, wherein all of R⁵, R⁶, R⁷, and R⁸ represent a hydrogen atom; or R⁶ represents a fluorine atom, and R⁵, R⁷, and R⁸ represent a hydrogen atom; or R⁵ represents a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, or amino, and R⁶, R⁷, and R⁸ represent a hydrogen atom; or R⁵ and R⁷ represent a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, or amino, and R⁶ and R⁸ represent a hydrogen atom.

Claim 17 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 1 to 16~~ claim 1, wherein R⁹ represents -(CH₂)_s-R⁵¹ wherein s is an integer of 1 to 4, and R⁵¹ represents a saturated three- to seven-membered carbocyclic group;

i-propyl optionally substituted by hydroxyl; t-butyl optionally substituted by hydroxyl; C₁₋₄ alkoxy; or -NR⁵²R⁵³ wherein R⁵² and R⁵³, which may be the same or different, represent a hydrogen atom, or C₁₋₄ alkyl optionally substituted by hydroxyl, or R⁵² and R⁵³ may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R⁹ represents a saturated five- to seven-membered carbocyclic group optionally substituted by one to three C₁₋₄ alkyl groups.

Claim 18 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein

X represents CH or N,

Z represents O or S,

R¹, R², and R³, which may be the same or different, represent
a hydrogen atom,

hydroxyl,

a halogen atom,

nitro,

amino,

C₁₋₆ alkyl,

C₂₋₆ alkenyl,

C₂₋₆ alkynyl, or

C₁₋₆ alkoxy,

the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, and C₁₋₆ alkoxy groups, which may be represented by R¹, R², and R³, are optionally substituted by hydroxyl; a halogen atom; C₁₋₆ alkoxy; C₁₋₆ alkylcarbonyl; carboxyl; C₁₋₆ alkoxycarbonyl; -(C=O)-NR¹⁰R¹¹ wherein R¹⁰ and

R^{11} , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{10} and R^{11} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C_{1-6} alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl group is further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl groups are further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C_{1-6} alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring;


one or two hydrogen atoms on the amino group, which may be represented by R^1 , R^2 , and R^3 , are optionally substituted by C_{1-6} alkyl which is further optionally substituted by hydroxyl or C_{1-6} alkoxy;

R^4 represents a hydrogen atom;

all of R^5 , R^6 , R^7 , and R^8 represent a hydrogen atom, or any one or two of R^5 , R^6 , R^7 , and R^8 represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino with all the remaining groups representing a hydrogen atom, and

R^9 represents C_{1-4} alkyl substituted by a substituent selected from the group consisting of a saturated three- to seven-membered carbocyclic group; i-propyl optionally substituted by hydroxyl; t-butyl optionally substituted by hydroxyl; C_{1-4} alkoxy; and $-NR^aR^b$ wherein R^a and R^b , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^a and R^b may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R^9 represents a saturated five- to seven-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.

Claim 19 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein said compound represented by formula (I) is represented by formula (Ia):



wherein

X represents CH or N ,

Z represents O or S ,

R^{101} and R^{104} represent a hydrogen atom,

R^{102} and R^{103} , which may be the same or different, represent

a hydrogen atom,

hydroxyl,

a halogen atom,

nitro,

cyano,

$-\text{NR}^{111}\text{R}^{112}$ wherein R^{111} and R^{112} , which may be the same or different, represent a

hydrogen atom or C_{1-4} alkyl,

$-(\text{C}=\text{O})\text{OR}^{113}$ wherein R^{113} represents a hydrogen atom or C_{1-4} alkyl,

$-(\text{C}=\text{O})\text{NR}^{114}\text{R}^{115}$ wherein R^{114} and R^{115} , which may be the same or different,

represent a hydrogen atom or C_{1-4} alkyl,

C_{1-6} alkoxy,

C_{1-6} alkyl,

C_{1-6} alkenyl, or

C_{1-6} alkynyl,

the C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkenyl, or C_{1-6} alkynyl are optionally substituted by hydroxyl; a halogen atom; C_{1-4} alkoxy; $-\text{NR}^{116}\text{R}^{117}$ wherein R^{116} and R^{117} , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl and the alkyl group is further optionally substituted by hydroxyl or C_{1-4} alkoxy; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the cyclic group is optionally substituted by hydroxyl, a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy,

all of R^{105} , R^{106} , R^{107} , and R^{108} represent a hydrogen atom, or any one or two of R^{105} , R^{106} , R^{107} , and R^{108} represent hydroxyl, C_{1-4} alkyl, C_{1-4} alkoxy, amino, nitro, or a halogen atom with all the remaining groups representing a hydrogen atom,

R^{109} represents $-(\text{CH}_2)_n\text{R}^{110}$ wherein n is 2, 3, or 4, and R^{110} represents *i*-propyl optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, or hydroxyl; *t*-butyl optionally substituted by


C₁₋₄ alkyl, C₁₋₄ alkoxy, or hydroxyl; or a three- to nine-membered saturated carbocyclic group optionally substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, or hydroxyl.

Claim 20 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein R¹⁰² and R¹⁰³, which may be the same or different, represent C₁₋₆ alkoxy and the C₁₋₆ alkoxy is optionally substituted by hydroxyl; a halogen atom; C₁₋₄ alkoxy; -NR¹¹⁶R¹¹⁷ wherein R¹¹⁶ and R¹¹⁷, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl and the alkyl group is further optionally substituted by hydroxyl or C₁₋₄ alkoxy; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the cyclic group is optionally substituted by hydroxyl, halogen atom, C₁₋₄ alkyl, or C₁₋₄ alkoxy.

Claim 21 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 20, wherein R¹⁰² and R¹⁰³, which may be the same or different, represent C₁₋₆ alkoxy in which the alkoxy group is optionally substituted by a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group and the cyclic group is further optionally substituted by hydroxyl, a halogen atom, C₁₋₄ alkyl, or C₁₋₄ alkoxy.


Claim 22 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 21, wherein R¹⁰² and R¹⁰³, which may be the same or different, represent C₁₋₄ alkoxy in which the alkoxy group is optionally substituted by a saturated five- to seven-membered heterocyclic group and the cyclic group is further optionally substituted by C₁₋₄ alkyl.

Claim 23 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 22, wherein said substituted C₁₋₄ alkoxy group is a group represented by



Claim 24 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 23, wherein n is 2.

Claim 25 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 22, wherein said substituted C₁₋₄ alkoxy group is a group represented by



Claim 26 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 25, wherein n is 2.

Claim 27 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 26~~ claim 19, wherein one of R¹⁰² and R¹⁰³ represents unsubstituted C₁₋₆ alkoxy and the other represents substituted C₁₋₆ alkoxy.

Claim 28 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 27, wherein R^{102} represents unsubstituted C_{1-6} alkoxy and R^{103} represents substituted C_{1-6} alkoxy.

Claim 29 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 28, wherein R^{102} represents methoxy.

Claim 30 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 29~~ claim 19, wherein X represents CH.

Claim 31 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 30~~ claim 19, wherein Z represents O.

Claim 32 (Currently Amended): The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 31~~ claim 19, wherein all of R^{105} , R^{106} , R^{107} , and R^{108} represent a hydrogen atom, or any one or two of R^{105} , R^{106} , R^{107} , and R^{108} represent C_{1-4} alkyl, C_{1-4} alkoxy, or a halogen atom with all the remaining groups representing a hydrogen atom.

Claim 33 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein R^{105} represents methoxy and R^{106} , R^{107} , and R^{108} represent a hydrogen atom.

Claim 34 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein R^{105} represents methyl and R^{106} , R^{107} , and R^{108} represent a hydrogen atom.


Claim 35 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein R^{105} represents a halogen atom and R^{106} , R^{107} , and R^{108} represent a hydrogen atom.

Claim 36 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 35, wherein the halogen atom represents a chlorine or fluorine atom.

Claim 37 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 35, wherein the halogen atom represents a fluorine atom.


Claim 38 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 32, wherein all of R^{105} , R^{106} , R^{107} , and R^{108} represent a hydrogen atom.

Claim 39 (Currently Amended): The ~~pharmaceutical composition~~ method according to any ~~one of claims 19 to 38~~ claim 19, wherein R^{109} is a group represented by



Claim 40 (Currently Amended): The pharmaceutical composition according to claim 39, wherein n is 2.

41. The ~~pharmaceutical composition~~ method according to ~~any one of claims 19 to 38~~ claim 19, wherein R¹⁰⁹ is a group represented by




Claim 42 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 41, wherein n is 2.

Claim 43 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein the compound represented by formula (Ia) is 1-(3,3-dimethyl-butyl)-3-{3-fluoro-4-[6-methoxy-7-(2-piperidin-1-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-urea.

Claim 44 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein the compound represented by formula (Ia) is 1-(2-cyclopentyl-ethyl)-3-{3-fluoro-4-[6-methoxy-7-(2-piperidin-1-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-urea.

Claim 45 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 19, wherein the compound represented by formula (Ia) is 1-(2-cyclopentyl-ethyl)-3-{2-fluoro-4-[6-methoxy-7-(2-piperidin-1-yl-ethoxy)-quinolin-4-yloxy]-phenyl}-urea.

Claim 46 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 1, wherein the compound represented by formula (I) is represented by formula (II):



wherein

R^{15} and R^{16} , which may be the same or different, represent $-O-(CH_2)_r-R^{22}$ wherein r is an integer of 0 to 6, $-(CH_2)_r-$ is optionally substituted by C_{1-6} alkyl, hydroxyl, or a halogen atom, and R^{22} represents a hydrogen atom; hydroxyl; a halogen atom; C_{1-6} alkoxy; C_{1-6} alkylcarbonyl; carboxyl; C_{1-6} alkoxycarbonyl; $-(C=O)-NR^{23}R^{24}$ wherein R^{23} and R^{24} , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl optionally substituted by hydroxyl, or R^{23} and R^{24} may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group; amino in which one or two hydrogen atoms on the amino group are optionally substituted by C_{1-6} alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and the C_{1-6} alkyl group is further optionally substituted by hydroxyl, C_{1-6} alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the carbocyclic or heterocyclic group is optionally substituted by hydroxyl, an oxygen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, or a saturated or unsaturated three- to

eight-membered carbocyclic or heterocyclic group, the C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl groups are further optionally substituted by hydroxyl, C₁₋₆ alkoxy, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, and, when the carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated five- to seven-membered carbocyclic or heterocyclic ring,

all of R¹⁷, R¹⁸, R¹⁹, and R²⁰ represent a hydrogen atom, or any one or two of R¹⁷, R¹⁸, R¹⁹, and R²⁰ represent a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, or amino with all the remaining groups representing a hydrogen atom, and

R²¹ represents -(CH₂)_t-R⁶¹ wherein t is an integer of 1 to 4 and R⁶¹ represents a saturated three- to seven-membered carbocyclic group; i-propyl optionally substituted by hydroxyl; t-butyl optionally substituted by hydroxyl; C₁₋₄ alkoxy; or -NR⁶²R⁶³ wherein R⁶² and R⁶³, which may be the same or different, represent a hydrogen atom, or C₁₋₄ alkyl optionally substituted by hydroxyl, or R⁶² and R⁶³ may combine with a nitrogen atom attached thereto to form a saturated five- or six-membered heterocyclic group, or R²¹ represents a saturated five- to seven-membered carbocyclic group optionally substituted by one to three C₁₋₄ alkyl groups.

Claim 47 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 46, wherein R¹⁵ and R¹⁶ represent -O-(CH₂)_r-H wherein r is an integer of 1 to 4 and the -(CH₂)_r- part is unsubstituted, or any one of R¹⁵ and R¹⁶ ~~represents~~ represents -O-(CH₂)_r-H wherein r is an integer of 1 to 4 and the -(CH₂)_r- part is unsubstituted with the other representing -O-(CH₂)_r-R²² wherein r is an integer of 1 to 4, the -(CH₂)_r- part is

unsubstituted, and R^{22} represents optionally substituted amino or an optionally substituted saturated three- to eight-membered heterocyclic group,

all of R^{17} , R^{18} , R^{19} , and R^{20} represent a hydrogen atom, or any one or two of R^{17} , R^{18} , R^{19} , and R^{20} represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino with all the remaining groups representing a hydrogen atom, and

R^{21} represents $-(CH_2)_t-R^{61}$, wherein t is an integer of 1 to 4 and R^{61} represents a saturated five- to seven-membered carbocyclic group; i-propyl; t-butyl optionally substituted by hydroxyl; C_{1-4} alkoxy; or $-NR^{62}R^{63}$ wherein R^{62} and R^{63} , which may be the same or different, represent C_{1-4} alkyl, or R^{21} represents a five- to seven-membered carbocyclic group optionally substituted by 1 to 3 C_{1-4} alkyl groups.


Claim 48 (Currently Amended): The ~~pharmaceutical composition~~ method according to claim 46, wherein R^{15} and R^{16} represent $-O-(CH_2)_r-H$ wherein r is an integer of 1 to 4 and the $-(CH_2)_r-$ part is unsubstituted, or any one of R^{15} and R^{16} represents $-O-(CH_2)_r-H$ wherein r is an integer of 1 to 4 and the $-(CH_2)_r-$ part is unsubstituted with the other representing $-O-(CH_2)_r-R^{22}$ wherein r is an integer of 1 to 4, the $-(CH_2)_r-$ part is unsubstituted, and R^{22} represents optionally substituted amino or an optionally substituted saturated three- to eight-membered heterocyclic group,

all of R^{17} , R^{18} , R^{19} , and R^{20} represent a hydrogen atom; or R^{18} represents a fluorine atom, and R^{17} , R^{19} , and R^{20} represent a hydrogen atom; or R^{17} represents a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy, and R^{18} , R^{19} , and R^{20} represent a hydrogen atom; or R^{17} and R^{19} represent a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy, and R^{18} and R^{20} represent a hydrogen atom, and

R^{21} represents $-(CH_2)_t-R^{61}$, wherein t is an integer of 2 or 3 and R^{61} represents a saturated five- to seven-membered carbocyclic group or t -butyl, or R^{21} represents a five- to seven-membered carbocyclic group optionally substituted by one to three C_{1-4} alkyl groups.


Claims 49-50 (Canceled).

Claim 51 (Original). A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:



wherein X , Z , R^{101} , R^{102} , R^{103} , R^{104} , R^{105} , R^{106} , R^{107} , R^{108} , and R^{109} are as defined in claim 19.

Claim 52 (Original): A compound represented by formula (II) or a pharmaceutically acceptable salt or solvate thereof:



wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, and R²¹ are as defined in claim 46.

Claim 53 (Original): A pharmaceutical composition comprising a compound according to claim 51 or 52 or a pharmaceutically acceptable salt or solvate thereof.